Alpha Diallo
0
All posts from Alpha Diallo
Alpha Diallo in Alpha Diallo,

Extended FDA Review drags Mannkind

 (Image source: bizmology.hoovers.com)

Shares of MannKind Corporation (NASDAQ:MNKD) are tumbling this morning after the FDA extended the review process for its inhaled insulin drug Afrezza. MannKind will receive an answer from the FDA until July 15th. Last week, the FDA’s Advisory Committee unanimous recommended approval of Afrezza. If you want to learn more about Afreeza, check out my earlier blog post titled “MannKind Corporation receives approval from FDA Advisory Committee for new insulin control”.